|
Gene: DYNLL2 |
Gene summary for DYNLL2 |
Gene summary. |
Gene information | Species | Human | Gene symbol | DYNLL2 | Gene ID | 140735 |
Gene name | dynein light chain LC8-type 2 | |
Gene Alias | DNCL1B | |
Cytomap | 17q22 | |
Gene Type | protein-coding | GO ID | GO:0006996 | UniProtAcc | Q96FJ2 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
140735 | DYNLL2 | P2T-E | Human | Esophagus | ESCC | 1.62e-11 | 1.95e-01 | 0.1177 |
140735 | DYNLL2 | P4T-E | Human | Esophagus | ESCC | 1.67e-09 | 1.61e-01 | 0.1323 |
140735 | DYNLL2 | P5T-E | Human | Esophagus | ESCC | 4.31e-08 | 9.10e-02 | 0.1327 |
140735 | DYNLL2 | P8T-E | Human | Esophagus | ESCC | 8.26e-17 | 2.36e-01 | 0.0889 |
140735 | DYNLL2 | P9T-E | Human | Esophagus | ESCC | 1.90e-10 | 1.05e-01 | 0.1131 |
140735 | DYNLL2 | P10T-E | Human | Esophagus | ESCC | 1.37e-14 | 1.06e-01 | 0.116 |
140735 | DYNLL2 | P12T-E | Human | Esophagus | ESCC | 1.17e-08 | 1.14e-01 | 0.1122 |
140735 | DYNLL2 | P15T-E | Human | Esophagus | ESCC | 9.78e-08 | 1.96e-01 | 0.1149 |
140735 | DYNLL2 | P16T-E | Human | Esophagus | ESCC | 3.75e-16 | 7.07e-02 | 0.1153 |
140735 | DYNLL2 | P20T-E | Human | Esophagus | ESCC | 2.10e-04 | 4.13e-02 | 0.1124 |
140735 | DYNLL2 | P21T-E | Human | Esophagus | ESCC | 4.85e-18 | 1.94e-01 | 0.1617 |
140735 | DYNLL2 | P22T-E | Human | Esophagus | ESCC | 4.51e-18 | 3.26e-01 | 0.1236 |
140735 | DYNLL2 | P23T-E | Human | Esophagus | ESCC | 1.61e-18 | 4.77e-01 | 0.108 |
140735 | DYNLL2 | P24T-E | Human | Esophagus | ESCC | 5.32e-07 | -6.28e-03 | 0.1287 |
140735 | DYNLL2 | P26T-E | Human | Esophagus | ESCC | 1.87e-14 | 1.34e-01 | 0.1276 |
140735 | DYNLL2 | P27T-E | Human | Esophagus | ESCC | 4.02e-11 | 2.39e-02 | 0.1055 |
140735 | DYNLL2 | P28T-E | Human | Esophagus | ESCC | 6.59e-26 | 3.29e-01 | 0.1149 |
140735 | DYNLL2 | P30T-E | Human | Esophagus | ESCC | 1.39e-09 | 5.05e-01 | 0.137 |
140735 | DYNLL2 | P31T-E | Human | Esophagus | ESCC | 6.58e-16 | 2.06e-01 | 0.1251 |
140735 | DYNLL2 | P32T-E | Human | Esophagus | ESCC | 1.28e-14 | 2.32e-01 | 0.1666 |
Page: 1 2 3 4 5 6 7 8 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa05132 | Colorectum | AD | Salmonella infection | 102/2092 | 249/8465 | 7.65e-09 | 1.28e-07 | 8.17e-08 | 102 |
hsa04962 | Colorectum | AD | Vasopressin-regulated water reabsorption | 19/2092 | 44/8465 | 5.48e-03 | 2.48e-02 | 1.58e-02 | 19 |
hsa051321 | Colorectum | AD | Salmonella infection | 102/2092 | 249/8465 | 7.65e-09 | 1.28e-07 | 8.17e-08 | 102 |
hsa049621 | Colorectum | AD | Vasopressin-regulated water reabsorption | 19/2092 | 44/8465 | 5.48e-03 | 2.48e-02 | 1.58e-02 | 19 |
hsa051322 | Colorectum | SER | Salmonella infection | 77/1580 | 249/8465 | 1.56e-06 | 2.35e-05 | 1.71e-05 | 77 |
hsa051323 | Colorectum | SER | Salmonella infection | 77/1580 | 249/8465 | 1.56e-06 | 2.35e-05 | 1.71e-05 | 77 |
hsa051324 | Colorectum | MSS | Salmonella infection | 92/1875 | 249/8465 | 5.23e-08 | 9.74e-07 | 5.97e-07 | 92 |
hsa049622 | Colorectum | MSS | Vasopressin-regulated water reabsorption | 17/1875 | 44/8465 | 9.76e-03 | 3.55e-02 | 2.18e-02 | 17 |
hsa051325 | Colorectum | MSS | Salmonella infection | 92/1875 | 249/8465 | 5.23e-08 | 9.74e-07 | 5.97e-07 | 92 |
hsa049623 | Colorectum | MSS | Vasopressin-regulated water reabsorption | 17/1875 | 44/8465 | 9.76e-03 | 3.55e-02 | 2.18e-02 | 17 |
hsa051326 | Colorectum | MSI-H | Salmonella infection | 43/797 | 249/8465 | 5.91e-05 | 8.33e-04 | 6.98e-04 | 43 |
hsa051327 | Colorectum | MSI-H | Salmonella infection | 43/797 | 249/8465 | 5.91e-05 | 8.33e-04 | 6.98e-04 | 43 |
hsa05132211 | Esophagus | ESCC | Salmonella infection | 191/4205 | 249/8465 | 6.51e-19 | 5.45e-17 | 2.79e-17 | 191 |
hsa0496223 | Esophagus | ESCC | Vasopressin-regulated water reabsorption | 33/4205 | 44/8465 | 5.27e-04 | 1.78e-03 | 9.13e-04 | 33 |
hsa05132310 | Esophagus | ESCC | Salmonella infection | 191/4205 | 249/8465 | 6.51e-19 | 5.45e-17 | 2.79e-17 | 191 |
hsa0496233 | Esophagus | ESCC | Vasopressin-regulated water reabsorption | 33/4205 | 44/8465 | 5.27e-04 | 1.78e-03 | 9.13e-04 | 33 |
hsa0513222 | Liver | Cirrhotic | Salmonella infection | 121/2530 | 249/8465 | 2.47e-10 | 5.13e-09 | 3.16e-09 | 121 |
hsa0513232 | Liver | Cirrhotic | Salmonella infection | 121/2530 | 249/8465 | 2.47e-10 | 5.13e-09 | 3.16e-09 | 121 |
hsa0513242 | Liver | HCC | Salmonella infection | 178/4020 | 249/8465 | 5.90e-15 | 1.98e-13 | 1.10e-13 | 178 |
hsa049624 | Liver | HCC | Vasopressin-regulated water reabsorption | 30/4020 | 44/8465 | 4.41e-03 | 1.32e-02 | 7.34e-03 | 30 |
Page: 1 2 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
DYNLL2 | SNV | Missense_Mutation | novel | c.175N>A | p.Gly59Ser | p.G59S | Q96FJ2 | protein_coding | deleterious(0) | probably_damaging(0.986) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
DYNLL2 | SNV | Missense_Mutation | c.202N>T | p.His68Tyr | p.H68Y | Q96FJ2 | protein_coding | deleterious(0.04) | benign(0.181) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
DYNLL2 | SNV | Missense_Mutation | novel | c.116C>T | p.Ala39Val | p.A39V | Q96FJ2 | protein_coding | tolerated(0.12) | possibly_damaging(0.539) | TCGA-B5-A3FA-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
DYNLL2 | SNV | Missense_Mutation | novel | c.30N>A | p.Asn10Lys | p.N10K | Q96FJ2 | protein_coding | deleterious(0.02) | possibly_damaging(0.644) | TCGA-B5-A5OC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Chemotherapy | cisplatin | SD |
DYNLL2 | SNV | Missense_Mutation | c.205G>A | p.Glu69Lys | p.E69K | Q96FJ2 | protein_coding | deleterious(0.03) | benign(0.382) | TCGA-BS-A0UV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
DYNLL2 | SNV | Missense_Mutation | rs745581029 | c.64N>A | p.Val22Ile | p.V22I | Q96FJ2 | protein_coding | tolerated(0.52) | benign(0.03) | TCGA-EY-A215-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
DYNLL2 | SNV | Missense_Mutation | novel | c.263C>T | p.Ser88Leu | p.S88L | Q96FJ2 | protein_coding | deleterious(0) | probably_damaging(0.958) | TCGA-49-4512-01 | Lung | lung adenocarcinoma | Female | >=65 | III/IV | Unspecific | PD | |
DYNLL2 | SNV | Missense_Mutation | c.58N>A | p.Asp20Asn | p.D20N | Q96FJ2 | protein_coding | tolerated(0.05) | benign(0.072) | TCGA-66-2758-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Chemotherapy | cisplatin | CR | |
DYNLL2 | deletion | In_Frame_Del | novel | c.140_151delNNNNNNNNNNNN | p.Lys48_Asn51del | p.K48_N51del | Q96FJ2 | protein_coding | TCGA-77-7465-01 | Lung | lung squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | SD | ||
DYNLL2 | SNV | Missense_Mutation | novel | c.31G>A | p.Ala11Thr | p.A11T | Q96FJ2 | protein_coding | tolerated(0.1) | benign(0.045) | TCGA-F7-A624-01 | Oral cavity | head & neck squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |